BLU — BELLUS Health Share Price
0.000.00%
Last trade - 00:00HealthcareSpeculativeMid Cap
- CA$2.47bn
- CA$2.06bn
- $0.02m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.06 | ||
| Price to Tang. Book | 5.85 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 124,423.34 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -24.42% | ||
| Return on Equity | -26.76% | ||
| Operating Margin | -602046.67% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.03 | 0.03 | 0.01 | 0.02 | 0.02 | 0.01 | n/a | -33.94% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
BELLUS Health Inc. is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. The Company's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The Company has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The Company is focused on initiating Phase III program. The Company is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.
Directors
- Francesco Bellini CHM (74)
- Roberto Bellini PRE (41)
- Ramzi Benamar CFO (48)
- Denis Garceau SVP (64)
- Francois Desjardins VFN (58)
- Tony Matzouranis VBD (48)
- Catherine Bonuccelli OTH (63)
- Sebastien Roy SEC (45)
- Pierre Larochelle LED (49)
- William Mezzanotte DRC (62)
- Youssef Bennani IND (60)
- Franklin Berger IND (71)
- Clarissa Desjardins IND (54)
- Joseph Rus IND (75)
- Last Annual
- December 31st, 2022
- Last Interim
- March 31st, 2023
- Incorporated
- April 12th, 2012
- Public Since
- June 22nd, 2000
- No. of Employees
- 74
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Toronto Stock Exchange
- Shares in Issue
- 126,812,170
- Address
- 275 Armand-Frappier Blvd, LAVAL, H7V 4A7
- Web
- https://bellushealth.com/
- Phone
- +1 4506804500
- Contact
- Ramzi Benamar
- Auditors
- KPMG LLP
Upcoming Events for BLU
Q3 2023 BELLUS Health Inc Earnings Release
Similar to BLU
AEterna Zentaris
Toronto Stock Exchange
Antibe Therapeutics
Toronto Stock Exchange
Appili Therapeutics
Toronto Stock Exchange
Aptose Biosciences
Toronto Stock Exchange
Avicanna
Toronto Stock Exchange
FAQ
What is the BELLUS Health share price?
As of Today at 19:03 UTC, shares in BELLUS Health are trading at CA$19.48. This share price information is delayed by 15 minutes.
How has the BELLUS Health share price performed this year?
Shares in BELLUS Health last closed at CA$19.48 and the price had moved by +60.63% over the past 365 days. In terms of relative price strength the BELLUS Health share price has outperformed the Toronto Stock Exchange 300 Composite Index by +51.65% over the past year.
What are the analyst and broker recommendations for BELLUS Health?
The overall consensus recommendation for BELLUS Health is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the BELLUS Health dividend yield?
BELLUS Health does not currently pay a dividend.
Does BELLUS Health pay a dividend?
BELLUS Health does not currently pay a dividend.
When does BELLUS Health next pay dividends?
BELLUS Health does not currently pay a dividend.
How do I buy BELLUS Health shares?
To buy shares in BELLUS Health you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of BELLUS Health?
As of the previous close price of CA$19.48, shares in BELLUS Health had a market capitalisation of CA$2.47bn.
Where are BELLUS Health shares listed?
Here are the trading details for BELLUS Health:
- Country of listing: Canada
- Exchange: TOR
- Ticker Symbol: BLU
What kind of share is BELLUS Health?
Based on an overall assessment of its quality, value and momentum BELLUS Health is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a BELLUS Health share price forecast for 2023?
The analyst consensus target price for shares in BELLUS Health is CA$20.66. That is 6.03% above the last closing price of CA$19.48.
Analysts covering BELLUS Health currently have a consensus Earnings Per Share (EPS) forecast of -$0.84 for the next financial year.
What is the trend in the BELLUS Health share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BELLUS Health. Over the past six months, its share price has outperformed the Toronto Stock Exchange 300 Composite Index by +69.78%.
As of the last closing price of CA$19.48, shares in BELLUS Health were trading +42.3% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the BELLUS Health PE Ratio?
The BELLUS Health PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$19.48.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of BELLUS Health?
BELLUS Health's management team is headed by:
- Francesco Bellini - CHM
- Roberto Bellini - PRE
- Ramzi Benamar - CFO
- Denis Garceau - SVP
- Francois Desjardins - VFN
- Tony Matzouranis - VBD
- Catherine Bonuccelli - OTH
- Sebastien Roy - SEC
- Pierre Larochelle - LED
- William Mezzanotte - DRC
- Youssef Bennani - IND
- Franklin Berger - IND
- Clarissa Desjardins - IND
- Joseph Rus - IND